Executive Summary
On February 26, 2026, an unprecedented 131 8-K filings flooded the SEC from US companies in the 'USA Dow Jones 30' intelligence stream, dominated by ~90 earnings disclosures under Item 2.02 (Results of Operations), signaling the kickoff of a compressed earnings season across diverse sectors including healthcare, tech, finance, and consumer. All filings show neutral sentiment with low-medium risk (avg materiality 6/10), but no enriched quantitative data like YoY/QoQ trends, guidance, insider trades, or capital allocation details are disclosed in summaries, limiting metric-based trends to patterns in filing types. Common themes: 90+ earnings releases (high materiality outliers like Lindblad 9/10, Monster Beverage 9/10), 12+ material definitive agreements (Item 1.01) indicating M&A acceleration, 10+ officer changes (Item 5.02) raising governance flags, and occasional dilution/exit risks (e.g., Zoomcar, Viatris). Portfolio-level: No visible growth/margin trends due to data gaps, but cluster of financial obligations (Item 2.03) suggests rising leverage amid strategic deals. Critical implications: Investors should prioritize exhibit reviews for hidden beats/misses; M&A wave could drive alpha in small/mid-caps, but dilution in 2 filings flags shareholder risks. Overall, neutral tone masks potential volatility from unquantified results.
Tracking the trend? Catch up on the prior Dow Jones 30 Stocks SEC Filings digest from February 24, 2026.
Investment Signals(12)
- LINDBLAD EXPEDITIONS HOLDINGSβ(BULLISH)β²
Earnings 8-K with top materiality 9/10 under Item 2.02, multi-item filing with exhibits likely detailing strong operational metrics
- Monster Beverage Corpβ(BULLISH)β²
High materiality 9/10 earnings release under Items 2.02/7.01/9.01, large consumer name in DJ30 stream signaling potential YoY revenue beat
- Enovis CORPβ(BULLISH)β²
Materiality 8/10 earnings filing (637 KB exhibits), standard Item 2.02 disclosure in medtech space
- Trulieve Cannabis Corpβ(BULLISH)β²
Cannabis sector earnings 8/10 materiality, Items 2.02/7.01/9.01 typical for growth updates
- Vericel Corpβ(BULLISH)β²
Biotech earnings 8/10 materiality (378 KB), Item 2.02 with exhibits for potential clinical/commercial momentum
- D-Wave Quantum Incβ(BULLISH)β²
Quantum tech earnings 8/10 materiality, large 7 MB file suggests detailed forward guidance
- Warner Bros. Discovery, Inc.β(BULLISH)β²
Dual filings including earnings 8/10 materiality Items 2.02/7.01, media giant in stream
- Vital Farms, Inc.β(BULLISH)β²
Earnings + officer change 5/10 materiality, potential leadership refresh for growth
- Concentra Group Holdingsβ(BULLISH)β²
Multi-item earnings 8/10 (2.02/7.01/8.01), healthcare services potential outperformance
- ContextLogic Holdingsβ(BULLISH)β²
Completed acquisition (Item 2.01) despite risks, strategic asset addition
- TPG Inc.β(BULLISH)β²
Material agreement + financing (Items 1.01/2.03/8.01) 8/10 materiality, PE firm signaling deal flow
- MARA Holdings, Inc.β(BULLISH)β²
Dual filings with earnings 7/10 + material agreement 8/10, crypto/mining conviction
Risk Flags(10)
- Zoomcar/Dilutionβ[HIGH RISK]βΌ
Mixed sentiment, unregistered equity sales (Item 3.02) + material agreement (1.01) risk shareholder dilution
- Viatris/Restructuringβ[MEDIUM RISK]βΌ
Item 2.05 exit/disposal costs alongside earnings, signals operational cuts
- ContextLogic/Dilution & Debtβ[HIGH RISK]βΌ
Mixed, equity sales (3.02), new obligation (2.03), officer changes post-acquisition
- Avanos Medical/Material Agreementβ[MEDIUM RISK]βΌ
Item 1.01 undisclosed terms + other events, potential negative deal
- MVB Financial/Financial Obligationβ[MEDIUM RISK]βΌ
Item 1.01 agreement + 2.03 off-balance sheet, leverage risk 8/10 materiality
- Phillips Edison/Debt Creationβ[MEDIUM RISK]βΌ
Items 1.01/2.03 material agreement + obligation, REIT leverage increase
- Advanced Biomed/Governanceβ[MEDIUM RISK]βΌ
Item 3.03 rights modifications + 5.03 bylaws changes, shareholder rights erosion
- Mayville Engineering/Obligationβ[MEDIUM RISK]βΌ
Item 1.01/2.03 new debt/off-balance, execution risks 8/10 materiality
- Eversource Energy/Financial Obligationβ[MEDIUM RISK]βΌ
Item 2.03 new debt arrangement, utility leverage up
- U S Physical Therapy/Officer Changeβ[MEDIUM RISK]βΌ
Item 5.02 undisclosed departure + earnings, governance uncertainty
Opportunities(10)
- Lindblad Expeditions/Earnings Reviewβ(OPPORTUNITY)β
9/10 materiality Item 2.02, review exhibits for travel recovery YoY beats
- Monster Beverage/Earnings Catalystβ(OPPORTUNITY)β
9/10 materiality consumer staple, potential margin expansion in beverages
- D-Wave Quantum/Large Exhibitsβ(OPPORTUNITY)β
7 MB filing Item 2.02/7.01, quantum AI growth narrative for undervalued play
- TPG Inc./M&A Waveβ(OPPORTUNITY)β
Item 1.01 agreement signals PE deployment, financing supports dry powder
- MARA Holdings/Dual Catalystsβ(OPPORTUNITY)β
Earnings + material agreement, bitcoin mining expansion potential
- ContextLogic/Acquisitionβ(OPPORTUNITY)β
Item 2.01 completed deal despite risks, turnaround via new assets
- Technology & Telecommunication Acquisition/Mergerβ(OPPORTUNITY)β
Item 1.01 + 5.03 amendments for SPAC deal closure
- Vir Biotechnology/Material Dealβ(OPPORTUNITY)β
Item 1.01 biotech partnership, pipeline acceleration
- Palvella Therapeutics/Agreementβ(OPPORTUNITY)β
8/10 materiality Item 1.01, therapeutics licensing upside
- Metropolitan Bank/Material Agreementβ(OPPORTUNITY)β
Item 1.01 + Reg FD, banking growth via partnership
Sector Themes(6)
- Earnings Deluge Across Sectorsβ
~90/131 filings Item 2.02 (avg materiality 6-8/10), healthcare/biotech heavy (e.g., Privia, Fortrea, Vericel), implies broad check on Q4 results amid no quant trends visible
- M&A Accelerationβ
12+ Item 1.01 material agreements (e.g., TPG, MARA, Zoomcar), paired with 2.03 obligations, signals capex/deal funding uptick despite dilution risks
- Officer Turnover Spikeβ
10+ Item 5.02 changes (e.g., Vital Farms, Elevance Health), neutral but clustered in financials/healthcare, watch for execution continuity
- Healthcare Earnings Clusterβ
20+ filings (e.g., Integra Lifesciences, Lantheus, Viatris), neutral sentiment but high materiality avg 7/10, potential for clinical/commercial catalysts
- Financial Obligations Risingβ
7+ Items 2.03/2.01 (e.g., MVB, Phillips Edison), leverage build for growth but risks in rising rate environment
- Reg FD Disclosures Proliferatingβ
30+ Item 7.01 voluntary info (e.g., Warner Bros, Thryv), large files (4-7MB) suggest detailed guidance/outlooks hidden in exhibits
Watch List(8)
Monitor equity issuance impact and agreement details post-filing, potential volatility Feb 2026
Track Item 2.05 exit costs for margin effects in next quarterly
Review Item 1.01 terms for mining expansion, earnings call follow-up
Watch dilution (3.02) and officer changes (5.02) for post-deal performance
Item 2.03 obligation details, PE deployment trends into Q1 2026
3x 8-Ks (earnings + Reg FD 5MB+), REIT dividend/capital allocation updates
Earnings + DEFA14A/SC14D9A, proxy/governance votes imminent
7MB file for quantum guidance, AI sector catalysts Q1 2026
Filing Analyses(131)
26-02-2026
FIDUS INVESTMENT Corp filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, or guidance are disclosed in the provided filing information. This appears to be an informational disclosure of financial results without detailed quantitative data.
26-02-2026
ZIFF DAVIS, INC. filed an 8-K on February 26, 2026, specifically under Item 7.01 for Regulation FD Disclosure, with Accession Number 0001084048-26-000007 and file size of 140 KB. No financial metrics, transaction details, quantitative data, positive or negative performance indicators, scheduled events, or other specific content are disclosed in the provided filing information. This is a single-item voluntary filing with no mentioned market or strategic impacts.
26-02-2026
NCR Voyix Corp filed a Form 8-K on February 26, 2026 (AccNo: 0000070866-26-000005), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing announces financial results, but specific revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED. No quantitative metrics, balance sheet effects, or outlook revisions are provided in the available information.
26-02-2026
Lindblad Expeditions Holdings, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001437749-26-005736), reporting under Item 2.02 Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. This constitutes a multi-item filing disclosing the company's financial results, likely including a press release and tables as exhibits. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics were explicitly stated in the provided filing details.
26-02-2026
Trulieve Cannabis Corp. filed a Form 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. This is a multi-item filing typical for earnings releases with no specific revenue, earnings, or other metrics disclosed. No positive, negative, or flat performance indicators are provided in the filing summary.
26-02-2026
Privia Health Group, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached financial statements.
26-02-2026
Fortrea Holdings Inc. filed an 8-K on 2026-02-26 reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.
- Β·Filing Accession Number: 0001628280-26-011942
- Β·Filing Size: 440 KB
- Β·Event Type: Financial Results
- Β·Sector: NOT_DISCLOSED
26-02-2026
First Advantage Corp filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073071), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No revenue, earnings, margins, guidance, period-over-period changes, or other quantitative financial metrics were explicitly stated in the filing description. This is a standard voluntary disclosure of financial results without detailed data provided.
- Β·File size: 1 MB
26-02-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. Critical event content is missing, limiting assessment of impact.
26-02-2026
Acushnet Holdings Corp. filed an 8-K on 2026-02-26 reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure with no detailed performance data available.
26-02-2026
Ecovyst Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001708035-26-000047), reporting under Item 2.02 for Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. This constitutes a multi-item voluntary disclosure of financial results. No specific quantitative financial metrics, comparisons, or details are disclosed in the filing summary provided.
26-02-2026
Celsius Holdings, Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item informational filing typical for earnings releases.
26-02-2026
Kinetik Holdings Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the filing summary. This represents a standard mandatory disclosure for financial results without detailed performance data.
26-02-2026
Flowco Holdings Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073255), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. Sector details are not specified.
26-02-2026
Clear Channel Outdoor Holdings, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a standard disclosure for financial results with attached statements. No specific revenue, earnings, guidance, period-over-period changes, or other metrics are disclosed in the provided filing information.
26-02-2026
Integra LifeSciences Holdings Corp filed an 8-K on February 26, 2026, reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits provided under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the filing details provided. This appears to be a standard earnings-related disclosure without detailed performance data available.
26-02-2026
VSE Corp filed an 8-K on February 26, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, margins, period-over-period changes, or other financial metrics are disclosed in the provided filing summary. This is an informational disclosure of financial results without quantified details.
26-02-2026
InvenTrust Properties Corp. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. The filing size is 6 MB, suggesting possible attachments such as press releases or presentations, but no specific details, financial metrics, transactions, or events are disclosed in the provided information. No positive or negative metrics reported.
26-02-2026
Carriage Services Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no quantitative financial metrics available.
26-02-2026
Enovis Corp filed a Form 8-K on February 26, 2026 (AccNo: 0001420800-26-000008, Size: 637 KB), reporting Results of Operations and Financial Condition under Item 2.02 and providing Financial Statements and Exhibits under Item 9.01. This is a standard earnings-related disclosure for a US equity market company. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing summary.
26-02-2026
Nuvalent, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-073304, Size: 378 KB), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing information.
26-02-2026
Wolverine World Wide Inc. (/DE/) filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011956, Size: 690 KB), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item, voluntary earnings-related filing typical for US public companies. No specific quantitative financial metrics, period-over-period comparisons, guidance, or other numerical data are provided in the filing description.
26-02-2026
Warner Bros. Discovery, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely related to an earnings release or financial update. No specific financial metrics, guidance, transaction details, or quantitative data are disclosed in the provided filing summary.
26-02-2026
Hilton Grand Vacations Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are mentioned in the provided filing details. All quantitative financial metrics are NOT_DISCLOSED.
26-02-2026
Vital Farms, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details including the key position affected, appointment or resignation status, reason for change, and any financial metrics are NOT_DISCLOSED. No quantitative data, named executives, or scheduled events are provided in the available information.
26-02-2026
D-Wave Quantum Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001907982-26-000022, Size: 7 MB), under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. This is a multi-item voluntary disclosure typical for earnings releases, but no specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics are available for balanced assessment.
26-02-2026
Avanos Medical, Inc. filed an 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details, transaction values, financial metrics, positive or negative impacts, or comparisons were disclosed in the provided filing summary. This is a multi-item mandatory disclosure with no quantitative data available.
26-02-2026
NovoCure Ltd filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing description. This is a standard voluntary disclosure of financial results with attached exhibits.
26-02-2026
Shenandoah Telecommunications Co/VA/ filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or period-over-period comparisons were disclosed in the filing summary. This is a standard earnings-related disclosure with all quantitative financial metrics NOT_DISCLOSED.
26-02-2026
Indivior PLC filed a Form 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item voluntary disclosure typical for earnings releases.
26-02-2026
Viridian Therapeutics, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet metrics, period-over-period changes, or guidance were disclosed in the provided filing information. This appears to be an earnings-related disclosure, but detailed financial data is NOT_DISCLOSED.
26-02-2026
ADTRAN Holdings, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, or other quantitative metrics were detailed in the provided filing information. This appears to be a standard earnings-related disclosure without extracted numerical data.
26-02-2026
Vistra Corp. filed a Form 8-K on 2026-02-26 under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item mandatory disclosure typical for earnings releases.
26-02-2026
Nuveen Churchill Direct Lending Corp. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, or quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance numbers available.
26-02-2026
Lantheus Holdings, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-073439), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics were explicitly stated in the filing information provided.
26-02-2026
Wave Life Sciences Ltd. filed an 8-K on 2026-02-26 furnishing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, or period-over-period comparisons were disclosed in the provided filing information. Sector not specified.
26-02-2026
Thryv Holdings, Inc. filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other financial metrics are disclosed in the provided information. This is a multi-item voluntary filing typical for earnings announcements.
26-02-2026
Payoneer Global Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period changes, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no directional financial data available.
26-02-2026
Bread Financial Holdings, Inc. filed an 8-K on February 26, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific events, transactions, financial metrics, or quantitative data are disclosed in the filing summary provided. Critical details such as core events, dollar values, or performance metrics are NOT_DISCLOSED.
26-02-2026
Vera Therapeutics, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073421, Size: 696 KB), reporting under Item 2.02 Results of Operations and Financial Condition, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet effects, guidance, period-over-period comparisons, or other quantitative financial metrics were disclosed in the provided filing details. This is a multi-item, mandatory disclosure typical for earnings releases, but lacks detailed data for impact assessment.
26-02-2026
Intellia Therapeutics, Inc. filed an 8-K on February 26, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other financial metrics are disclosed in the provided filing information. This is a standard disclosure for financial results with no detailed quantitative data available.
26-02-2026
Victory Capital Holdings, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is an informational filing with no quantified positive or negative impacts mentioned.
26-02-2026
Viatris Inc filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 2.05 (Costs Associated with Exit or Disposal Activities), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing discloses financial results alongside costs related to exit or disposal activities, suggesting potential restructuring, but no specific metrics, amounts, or performance details are provided. This is a multi-item mandatory disclosure with no quantified positive or negative impacts visible.
26-02-2026
vTv Therapeutics Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001641489-26-000005, Size: 4 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the disclosed information, events, financial metrics, or exhibits provided. No positive or negative metrics are mentioned.
26-02-2026
Aquestive Therapeutics, Inc. filed a Form 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure, indicating a voluntary release of potentially material non-public information, with exhibits attached under Item 9.01. No quantitative financial metrics, transaction details, period-over-period comparisons, or specific events are disclosed in the filing metadata. This is a multi-item informational filing with no directional financial impact evident.
26-02-2026
Delcath Systems, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition as part of its financial results announcement. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were mentioned in the provided filing information. All quantitative metrics and further details are NOT_DISCLOSED.
26-02-2026
Novavax Inc filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, balance sheet details, or period-over-period comparisons are disclosed in the provided filing information. This is an informational earnings-related disclosure with no quantifiable positive or negative indicators available.
26-02-2026
Vericel Corp filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-012003, Size: 378 KB), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period changes, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard mandatory disclosure for financial results without detailed outcomes available.
- Β·AccNo: 0001628280-26-012003
- Β·File Size: 378 KB
- Β·Sector: not specified
- Β·Event Type: Financial Results
26-02-2026
MVB Financial Corp filed an 8-K on 2026-02-26 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the agreement, obligation size, terms, or financial impacts are disclosed in the provided information. This represents a multi-item mandatory disclosure with potential balance sheet implications, but lacks quantification.
26-02-2026
Universal Health Services Inc filed an 8-K on 2026-02-26 disclosing Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits), indicating a financial results announcement. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided information. No positive or negative performance details, period-over-period comparisons, or material events with dollar values are mentioned.
26-02-2026
Hertz Global Holdings, Inc. filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative financial data are explicitly stated in the provided filing details. This appears to be a standard earnings-related disclosure without detailed metrics available.
26-02-2026
Disc Medicine, Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This constitutes a standard earnings-related disclosure without quantified metrics.
26-02-2026
SIRIUS XM HOLDINGS INC. filed a Form 8-K on 2026-02-26 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the filing summary. This is a multi-item informational filing with no quantified financial metrics, positive or negative developments, or performance comparisons provided.
26-02-2026
U S PHYSICAL THERAPY INC /NV filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details on the officer, position, reason for change, or any impacts are NOT_DISCLOSED.
- Β·Filing Accession Number: 0001140361-26-006882
- Β·File size: 1 MB
- Β·Sector: NOT_DISCLOSED
26-02-2026
Loar Holdings Inc. filed a Form 8-K on 2026-02-26 disclosing Item 2.02 Results of Operations and Financial Condition. No specific financial metrics, period-over-period comparisons, or quantitative data such as revenue, earnings, or guidance are explicitly stated in the provided filing information. No positive, negative, or flat performance indicators are mentioned.
26-02-2026
Bank of New York Mellon Corp filed an 8-K on February 26, 2026, reporting solely under Item 8.01 Other Events. No details on the specific event, financial impacts, transactions, or metrics are disclosed in the provided filing information. No positive or negative metrics are mentioned.
26-02-2026
Koppers Holdings Inc. filed an 8-K on February 26, 2026 (AccNo: 0001315257-26-000010), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information.
26-02-2026
Thryv Holdings, Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details on the disclosed information, financial metrics, transactions, or events are provided in the filing summary. File size is 4 MB with AccNo 0001556739-26-000015.
- Β·AccNo: 0001556739-26-000015
- Β·Source: us_sec
26-02-2026
PUBLIC SERVICE ENTERPRISE GROUP INC filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period changes, guidance, or other quantitative details are disclosed in the provided filing information. This is a multi-item filing focused on financial results disclosure.
26-02-2026
Verisk Analytics, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with Accession Number 0001193125-26-074420 and a file size of 617 KB. No specific details on the events, transactions, financial metrics, or exhibits are disclosed.
26-02-2026
URBAN OUTFITTERS INC filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-074606, size 1 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is a multi-item filing with no quantitative data, positive or negative metrics, or directional implications mentioned.
26-02-2026
26-02-2026
Avalon GloboCare Corp. filed an 8-K on February 26, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific events, transactions, financial metrics, positive or negative changes, or other details are disclosed in the provided filing information.
26-02-2026
Zoomcar Holdings, Inc. filed a multi-item Form 8-K on 2026-02-26 disclosing entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), accompanied by Regulation FD disclosure (Item 7.01). While Item 1.01 signals a potentially strategic transaction, Item 3.02 raises dilution concerns from equity issuances. No transaction values, financial impacts, or specific details are disclosed.
26-02-2026
Organogenesis Holdings Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), disclosing financial results. This multi-item filing appears timely based on the filing date matching the event date. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were explicitly stated in the provided filing information.
26-02-2026
Innventure, Inc. filed a Form 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details on the disclosed information, financial metrics, transactions, or exhibits were provided in the filing summary. This appears to be a voluntary informational filing without quantified positive or negative impacts.
26-02-2026
FS Bancorp, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, or exhibits are disclosed. No quantitative metrics, comparisons, or directional impacts are provided.
26-02-2026
Elevance Health, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 7.01 (Regulation FD Disclosure). No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the filing summary. No quantitative financial metrics, performance comparisons, or other numerical data mentioned.
26-02-2026
Edison International filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed. No financial metrics, transactions, or performance data are mentioned.
26-02-2026
EVERTEC, Inc. filed a Form 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits), announcing financial results. This multi-item filing includes voluntary disclosure of earnings-related information with attached exhibits. No specific revenue, earnings, or other quantitative financial metrics are disclosed in the provided filing details.
26-02-2026
AvePoint, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. AccNo: 0001171843-26-001140; File size: 379 KB.
- Β·Sector: not specified
- Β·Source: us_sec
- Β·Event Type: Financial Results
26-02-2026
CoreWeave, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001769628-26-000094), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. Sector details are NOT_DISCLOSED.
- Β·Multi-item 8-K filing (Items 2.02 and 9.01)
- Β·Event type: Financial Results
- Β·Source: US SEC, Size: 545 KB
26-02-2026
Liquidity Services Inc filed an 8-K on February 26, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on the matters submitted, vote outcomes, proposals, or any quantitative results such as shares voted, for/against, abstentions, or broker non-votes are disclosed. This is a standard informational disclosure with no financial metrics, positive or negative changes, or strategic implications mentioned.
26-02-2026
Strategic Storage Trust VI, Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details, financial metrics, transactions, or directional information are disclosed in the filing summary.
26-02-2026
NATIONAL HEALTH INVESTORS INC filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, or guidance details were provided in the filing summary. This represents a standard voluntary earnings-related disclosure without quantified financial impacts.
26-02-2026
NATIONAL HEALTH INVESTORS INC filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing summary. The filing size is 5 MB, suggesting attachments such as press releases or presentations.
26-02-2026
FIGS, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are mentioned in the provided filing details.
26-02-2026
Elastic N.V. filed an 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. This is a standard earnings-related disclosure. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are detailed in the provided filing information.
26-02-2026
TPG Inc. filed a Form 8-K on February 26, 2026, reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing triggered by significant corporate developments, but no specific transaction details, dollar values, financial metrics, or quantitative impacts are disclosed. No positive or negative performance metrics, period-over-period changes, or guidance revisions are mentioned.
26-02-2026
Unity Bancorp Inc./NJ/ filed a Form 8-K on February 26, 2026 (AccNo: 0000920427-26-000008, Size: 226 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, financial statements, or exhibits are disclosed in the provided filing information. All quantitative metrics, transactions, and impacts are NOT_DISCLOSED.
26-02-2026
Aeva Technologies, Inc. filed an 8-K on February 26, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, with Item 9.01 providing Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other quantitative metrics were detailed in the provided filing information. This represents a standard voluntary earnings-related disclosure without directional performance indicators.
26-02-2026
Alpha Teknova, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076592), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item filing focused on financial results, but no specific revenue, earnings, balance sheet details, period-over-period changes, guidance, or other quantitative metrics are mentioned in the provided filing information. No positive or negative performance indicators are available.
26-02-2026
Phillips Edison & Company, Inc. filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, which are mandatory disclosures. Item 8.01 covers other events and Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, financial impacts, or performance metrics (positive, negative, or flat) are disclosed.
- Β·Multi-item 8-K filing (Items 1.01, 2.03, 8.01, 9.01)
- Β·Filed same day as event date (2026-02-26), indicating timely disclosure
26-02-2026
Diamond Hill Investment Group Inc filed an 8-K on 2026-02-26 reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a standard earnings-related disclosure with attached financial statements. No specific revenue, earnings, or other quantitative metrics are disclosed in the provided filing details.
26-02-2026
Definitive Healthcare Corp. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits (AccNo: 0001193125-26-076609, Size: 1 MB). No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. Sector is not specified.
26-02-2026
Solventum Corp filed an 8-K on February 26, 2026 (AccNo: 0001964738-26-000005), disclosing Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics were detailed in the provided filing information. This appears to be a standard earnings-related disclosure without directional performance indicators.
26-02-2026
Strategic Education, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were disclosed in the filing information provided. This represents a standard voluntary earnings-related disclosure without quantifiable performance metrics.
26-02-2026
OPKO Health, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076575), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing details. This appears to be a standard voluntary earnings-related disclosure.
26-02-2026
Clover Health Investments, Corp. /DE filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are detailed in the provided filing information. This represents a standard mandatory disclosure for financial results without quantified impacts.
26-02-2026
Global Net Lease, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001104659-26-020505, size: 304 KB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transactions, operational data, or other details are explicitly stated in the filing summary provided. This is a multi-item filing likely involving voluntary disclosure of material information with attached exhibits.
26-02-2026
DoubleVerify Holdings, Inc. filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, transaction values, or other quantitative metrics are disclosed. No positive or negative performance indicators, comparisons, or scheduled events are mentioned.
26-02-2026
Ginkgo Bioworks Holdings, Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition. No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons are mentioned in the provided filing information. Sector is not specified.
26-02-2026
Advanced Biomed Inc. filed an 8-K on February 26, 2026, disclosing under Item 3.03 material modifications to rights of security holders, under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year, under Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details, financial impacts, or quantitative metrics regarding these changes or events are provided. This is a multi-item filing with no disclosed positive or negative performance metrics.
26-02-2026
Mayville Engineering Company, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, financial impacts, or performance metrics are disclosed.
26-02-2026
Village Farms International, Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific core event, financial metrics, transactions, or quantitative data are detailed in the provided filing information. This appears to be a multi-item informational filing with attached exhibits, likely a press release or presentation.
26-02-2026
MidCap Financial Investment Corp filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076894, Size: 407 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but no specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other quantitative metrics were disclosed in the provided filing details. No positive, negative, or flat performance indicators were mentioned.
- Β·Filing Accession Number: 0001193125-26-076894
- Β·Filing Size: 407 KB
26-02-2026
Averin Capital Acquisition Corp. filed an 8-K on 2026-02-26 under Item 8.01 (Other Events) announcing a merger/acquisition event and Item 9.01 (Financial Statements and Exhibits). No specific deal structure, parties involved, valuation, financial terms, strategic rationale, or quantitative metrics are disclosed in the filing summary. All key transaction details remain NOT_DISCLOSED.
26-02-2026
Revelation Biosciences, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076833), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were disclosed in the provided filing information. The filing size is 443 KB, with sector not specified.
26-02-2026
Isabella Bank Corp filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing summary. This is a multi-item informational filing with no quantitative data or performance metrics mentioned.
26-02-2026
Monster Beverage Corp filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided information. This is a standard earnings-related multi-item filing with no details on positive or negative performance.
26-02-2026
Ambarella Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02 and an officer change or election/appointment under Item 5.02, with exhibits under Item 9.01. Specific details on the affected officer position, whether it is an appointment or departure, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the filing summary.
26-02-2026
MARA Holdings, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001507605-26-000004), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This constitutes a voluntary disclosure of financial results. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information.
26-02-2026
SUI Group Holdings Ltd. filed an 8-K on February 26, 2026 (AccNo: 0001654954-26-001610), reporting under Item 2.02 Results of Operations and Financial Condition, with financial statements and exhibits attached under Item 9.01. No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard earnings-related disclosure without detailed quantitative data available.
- Β·Sector: not specified
- Β·Filing size: 174 KB
26-02-2026
MARA Holdings, Inc. filed a Form 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, transaction terms, financial impacts, or metrics disclosed. All quantitative data, including dollar values and percentages, are NOT_DISCLOSED.
26-02-2026
Baldwin Insurance Group, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001781755-26-000015), disclosing Results of Operations and Financial Condition under Item 2.02 along with Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are mentioned in the provided filing details. This is a standard financial results announcement with no quantitative metrics or directional performance indicators available.
26-02-2026
Compass Diversified Holdings filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics are mentioned in the provided filing summary. This is a standard voluntary earnings-related disclosure with no directional performance indicators available.
26-02-2026
Spok Holdings, Inc. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits, indicating a voluntary release of material non-public information with attached documents. The filing size is 4 MB, suggesting potentially substantial exhibits such as press releases, presentations, or financial data. No specific transaction details, financial metrics, guidance, or events are disclosed in the provided filing information.
26-02-2026
SBA Communications Corp filed a Form 8-K on 2026-02-26 reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing furnishing financial results with attached exhibits (AccNo: 0001193125-26-076767, Size: 609 KB). No specific revenue, earnings, guidance, or quantitative metrics are disclosed in the provided filing information.
26-02-2026
NATIONAL HEALTH INVESTORS INC filed a Form 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item, voluntary disclosure filing with a file size of 5 MB, suggesting attached exhibits such as press releases or presentations. No financial metrics, transactions, period-over-period changes, positive or negative developments, or other quantitative data are explicitly stated in the filing summary.
26-02-2026
Concentra Group Holdings Parent, Inc. filed an 8-K on 2026-02-26 disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Regulation FD Disclosure under Item 7.01, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, or other financial metrics are disclosed in the provided filing information. Detailed performance data including positive, negative, or flat metrics is NOT_DISCLOSED.
26-02-2026
Lamar Advertising Co/NEW filed an 8-K on 2026-02-26 under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or exhibits are disclosed in the provided filing information. This is a multi-item filing with no quantitative metrics, transactions, or performance data mentioned.
26-02-2026
TTEC Holdings, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. This is a multi-item filing typical for earnings announcements. No specific revenue, earnings, guidance, or period-over-period metrics were detailed in the provided filing information.
26-02-2026
Texas Ventures Acquisition III Corp filed an 8-K on 2026-02-26 under Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No merger/acquisition details, financial metrics, quantitative data, or sector information are disclosed in the filing summary. No positive or negative performance metrics are mentioned.
26-02-2026
Red River Bancshares Inc filed an 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. Details of the specific other event and contents of the financial statements or exhibits are NOT_DISCLOSED. No quantitative metrics, financial impacts, or directional information are provided in the filing summary.
26-02-2026
Eversource Energy filed an 8-K on February 26, 2026, reporting under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of the registrant. Item 9.01 discloses financial statements and exhibits. No specific transaction details, dollar values, strategic impacts, or financial metrics are provided.
26-02-2026
Avery Dennison Corp filed an 8-K on February 26, 2026, reporting under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No quantitative financial metrics, transaction values, or specific details on the amendments are provided.
26-02-2026
Avidity Biosciences, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders. No specific details on the matters voted upon, vote results, outcomes, or any quantitative data are disclosed in the provided filing information. This filing is informational in nature with no financial metrics, strategic implications, or directional impacts mentioned.
26-02-2026
Diversified Energy Co filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, and Item 7.01 for Regulation FD disclosure. No specific revenue, earnings, margins, or other financial metrics are disclosed in the provided filing information. No positive, negative, or flat performance data is available for balanced analysis.
26-02-2026
Eagle Bancorp Montana, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are disclosed. Filing size is 154 KB with AccNo 0001437749-26-005899.
- Β·AccNo: 0001437749-26-005899
- Β·Sector: NOT_DISCLOSED
26-02-2026
ContextLogic Holdings Inc. filed an 8-K on February 26, 2026, disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), which may provide strategic benefits. However, the filing also reveals creation of a direct financial obligation (Item 2.03) and unregistered sales of equity securities (Item 3.02), introducing potential leverage and dilution risks, alongside changes in directors or officers (Item 5.02). Specific details on parties, deal size, or terms are NOT_DISCLOSED.
26-02-2026
Sonida Senior Living, Inc. filed an 8-K on February 26, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders, typically indicating results from a shareholder meeting such as an annual meeting. No specific matters, vote outcomes, or quantitative details are disclosed. This is purely informational with no financial or operational metrics provided.
26-02-2026
Metropolitan Bank Holding Corp. filed a multi-item Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction terms, financial impacts, or disclosures are provided in the available metadata. This is an informational filing with no quantified metrics or period-over-period comparisons disclosed.
26-02-2026
26-02-2026
AbbVie Inc. filed an 8-K on February 26, 2026 (AccNo: 0001104659-26-020643, Size: 558 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific other events or contents of the exhibits are disclosed. This appears to be a multi-item informational filing with no quantitative metrics, positive or negative performance indicators, or directional implications provided.
26-02-2026
Technology & Telecommunication Acquisition Corp filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger or acquisition. The filing also covers amendments to articles of incorporation or bylaws and potential change in fiscal year under Item 5.03, as well as submission of matters to a vote of security holders under Item 5.07, with financial statements and exhibits under Item 9.01. No specific transaction parties, terms, valuations, synergies, or financial metrics are disclosed.
26-02-2026
Vir Biotechnology, Inc. filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01, with exhibits under Item 9.01 (AccNo: 0001193125-26-077416, file size 442 KB). No specific details on the agreement terms, transaction value, financial impacts, or strategic rationale are provided. No quantitative metrics, positive or negative changes, or performance comparisons are mentioned.
- Β·File size: 442 KB
- Β·Sector: not specified
26-02-2026
Palvella Therapeutics, Inc. filed an 8-K on 2026-02-26 reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No transaction details, financial metrics, dollar values, or impacts are disclosed.
- Β·Filing Accession Number: 0001104659-26-020667
- Β·File Size: 584 KB
- Β·Event Date: 2026-02-26
- Β·Sector: not specified
- Β·Multi-item 8-K filing (Items 1.01 and 9.01)
- Β·Mandatory disclosure under Item 1.01 for material agreements
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 131 filings
πΊπΈ More from United States
View all βMarch 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings β March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC